Johnson & Johnson News Headlines

JNJ 
$102.26
*  
0.06
0.06%
Get JNJ Alerts
*Delayed - data as of Jan. 26, 2015  -  Find a broker to begin trading JNJ now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    JNJ Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
How to Tell if a Dividend Is Safe
1/26/2015 7:02:01 PM - Motley Fool


How Will M&A ETFs Perform In 2015? Many Deals Lined Up
1/26/2015 6:42:00 PM - Investor's Business Daily


CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog
1/26/2015 4:45:00 PM - Zacks.com


How Much 'Extra' Return Are You Getting If You Reinvest Dividends?
1/26/2015 1:35:00 PM - Seeking Alpha


Jim Cramer Answers Twitter (TWTR) Questions on Johnson & Johnson, Alcoa, Mobileye, and Facebook
1/26/2015 1:15:00 PM - TheStreet


5 Things Johnson & Johnson's Management Wants You to Know
1/26/2015 1:04:02 PM - Motley Fool


Intuitive Surgical Set To Regain Momentum In 2015
1/26/2015 1:00:00 PM - Seeking Alpha


AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog
1/26/2015 10:50:00 AM - Investopedia


Pharmaceutical industry regulations
1/26/2015 10:06:00 AM - Market Realist


5 Cant-Miss Reasons Why Celgene Corporation Could Soar
1/26/2015 8:04:02 AM - Motley Fool


Johnson & Johnson Is Not Overvalued - This Company Could Have 35% Upside From Here
1/26/2015 7:11:00 AM - Seeking Alpha


CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog
1/26/2015 4:45:00 AM - Investopedia


My Roth Conversion Odyssey (Part 2)
1/25/2015 1:14:00 AM - Seeking Alpha


The Smart Way to Make Money in a Low Interest Rate Environment
1/24/2015 8:02:03 AM - Motley Fool


This Stock Could Become the Next Johnson & Johnson
1/24/2015 8:01:04 AM - Motley Fool


Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog
1/23/2015 5:20:00 PM - Zacks.com


Pharmaceutical industry supply chain
1/23/2015 4:06:00 PM - Market Realist


The Global Backdrop For S&P 500 Earnings
1/23/2015 2:45:00 PM - Seeking Alpha


Johnson & Johnson: No Real Earnings Growth Since 2007; And Don't Ignore Special Items
1/23/2015 12:15:00 PM - Seeking Alpha


Johnson & Johnson: 'Slightly Overvalued' Is No Reason To Sell
1/23/2015 11:53:00 AM - Seeking Alpha


XLV, JNJ, PFE, MRK: Large Outflows Detected at ETF
1/23/2015 11:12:27 AM - BNK Invest


Dow Movers: JNJ, V
1/23/2015 10:27:53 AM - BNK Invest


Investors Sold Johnson & Johnson For All the Wrong Reasons
1/23/2015 8:02:01 AM - Motley Fool


What Lessons Has Express Scripts Taught Us? The Future For The Pharmaceutical Industry
1/23/2015 7:30:00 AM - Seeking Alpha


Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog
1/23/2015 5:20:00 AM - Investopedia